Boehringer Ingelheim Backs R&D With Big Bucks
Reports Solid Set Of Financials For 2020
Jardiance and Ofev are growing strongly but the German drugmaker is also confident its pipeline will bear fruit, boosted by a rising research budget that represents almost 23% of sales.
You may also be interested in...
The family-owned German pharma dates back to 1885 and tries to keep up with its publicly traded peers by not mimicking everything they do, but with a “value by innovation” focus.
Cardiologists in Europe who have so far been unwilling to embrace the SGLT2 class now have two drugs approved for heart failure with reduced ejection fraction, with Jardiance soon to join Farxiga on the market, potentially attractive options especially for their diabetic patients.
AstraZeneca’s SGLT2 inhibitor produced 50% growth in Q1, and its new chronic kidney disease approval will give it an edge over Lilly and Boehringer’s Jardiance.